UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s What Happened

Shares of UCB SA (OTCMKTS:UCBJY) gapped down before the market opened on Thursday . The stock had previously closed at $142.88, but opened at $124.64. UCB shares last traded at $123.53, with a volume of 4,924 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Zacks Research upgraded UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Jefferies Financial Group raised UCB to a “moderate sell” rating in a report on Monday, June 22nd. Finally, Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

UCB Stock Up 2.9%

The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20. The company’s fifty day simple moving average is $143.51 and its two-hundred day simple moving average is $147.42.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.